首页> 美国卫生研究院文献>BMC Cancer >Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma
【2h】

Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

机译:间变性大细胞淋巴瘤中间变性淋巴瘤激酶/蛋白激酶B /哺乳动物靶标雷帕霉素信号通路的活化的预后意义和治疗潜力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroudActivation of the protein kinase B/mammalian target of rapamycin (AKT/mTOR) pathway has been demonstrated to be involved in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated tumorigenesis in anaplastic large cell lymphoma (ALCL) and correlated with unfavorable outcome in certain types of other cancers. However, the prognostic value of AKT/mTOR activation in ALCL remains to be fully elucidated. In the present study, we aim to address this question from a clinical perspective by comparing the expressions of the AKT/mTOR signaling molecules in ALCL patients and exploring the therapeutic significance of targeting the AKT/mTOR pathway in ALCL.
机译:已证明蛋白激酶B /哺乳动物雷帕霉素靶标(AKT / mTOR)途径的激活与间变性大细胞淋巴瘤(ALCL)的核蛋白-间变性淋巴瘤激酶(NPM-ALK)介导的肿瘤发生有关,并与不良预后相关在某些类型的其他癌症中。但是,ALCL中AKT / mTOR激活的预后价值仍有待充分阐明。在本研究中,我们旨在通过比较ALCL患者中AKT / mTOR信号分子的表达并探索在ALCL中靶向AKT / mTOR途径的治疗意义从临床角度解决此问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号